NormOxys, Inc.' Novel Oxygen-Enhancing Drug Candidate, OXY111A, Recognized as One of Windhover Information Inc.'s Top 10 Cardiovascular/Metabolic Projects to Watch
11/3/2010 11:41:14 AM
More...
|
NormOxys, Inc. Appoints Dr. Gerard Riedel as Vice President, Regulatory Affairs and Program Management
10/5/2010 10:48:51 AM
More...
|
NormOxys, Inc. Appoints Dr. John A. Hey Senior Vice President of Preclinical and Early Development
6/21/2010 7:15:51 AM
More...
|
NormOxys, Inc. Initiates Phase 1 Clinical Trial of Allosteric Effector of Hemoglobin, OXY111A
5/24/2010 10:40:59 AM
More...
|
NormOxys, Inc. Secures $17.5 Million Series B Financing to Advance Lead Drug Candidate into Clinical Studies for Two Diseases
5/24/2010 6:26:50 AM
More...
|